ESMO 2023 Bladder Cancer - Results from #20

Viewing 21-39 of 39 articles

ESMO 2023: Phase II Trial Compares Tobemstomig Alone or with Tiragolumab vs. Atezolizumab in Untreated Metastatic Urothelial Cancer

ESMO 2023: Biomarkers of Treatment - Related Toxicity in Advanced Urothelial Carcinoma Patients Treated with Enfortumab Vedotin: Analysis of UNITE Study

ESMO 2023: Staging of Muscle-Invasive Bladder Cancer: The Impact of PET Imaging [PET-MUSE]

ESMO 2023: SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 vs Intravesical BCG in Patients with BCG-Naive High-Risk Non–Muscle-Invasive Bladder Cancer

ESMO 2023: A Randomized Phase II Study of Atezolizumab plus Recombinant Human IL-7 (CYT107) Versus Atezolizumab Alone in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2023: Organ Preservation for Refractory Non-Muscle Invasive Bladder Cancer: A Surgeon's Perspective

ESMO 2023: Interim Results from the Phase 2 ARCADIA Trial: Activity of Cabozantinib + Durvalumab in Patients with Advanced Non-Urothelial-Carcinoma Variant Histologies or Urothelial Carcinoma After Platinum-Based Chemotherapy

ESMO 2023: A Phase 1b Single-Arm Trial of Bintrafusp Alfa for Pretreated, Locally Advanced/unresectable or Metastatic Urothelial Cancer

ESMO 2023: Radiotherapy in Bladder Preservation

ESMO 2023: Efficacy of a Tailored Approach with Nivolumab and Nivolumab + Ipilimumab as Immuno-Therapeutic Boost in Metastatic Urothelial Carcinoma – Final Results of TITAN-TCC

ESMO 2023: The Role of Systemic Therapy in Bladder Preservation for Muscle-Invasive Bladder Cancer

ESMO 2023: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Older Patients

ESMO 2023: Updated Results of PEANUT Trial: Pembrolizumab and Nab-Paclitaxel as Salvage Therapy for Platinum-Treated, Locally Advanced or Metastatic Urothelial Carcinoma

ESMO 2023: Invited Discussant: ICRA Trial & The Double Antibody Drug Conjugate (DAD) Trial

ESMO 2023: Invited Discussant: Phase 3 THOR Study & THOR-2 Cohort 1

ESMO 2023: ICRA: Efficacy of Paclitaxel with Tremelimumab +/- Durvalumab in Metastatic Urothelial Carcinoma After Progression on Platinum Chemotherapy and Anti-PD-(L)1

ESMO 2023: The Double Antibody Drug Conjugate (DAD) Phase I Trial: Sacituzumab Govitecan plus Enfortumab Vedotin as ≥ Second Line Therapy for Metastatic Urothelial Carcinoma

ESMO 2023: THOR Phase 3: Results of Erdafitinib vs Pembrolizumab in Pretreated Patients With Advanced or Metastatic Urothelial Cancer With Select Fibroblast Growth Factor Receptor Alterations

ESMO 2023: THOR-2 Cohort 1: Results of Erdafitinib vs Intravesical Chemotherapy for High-Risk Non Muscle Invasive Bladder Cancer with Select FGFR Alterations Who Received Prior BCG Treatment

1
2